Cita APA

Roviello, G., Petrioli, R., Nardone, V., Rosellini, P., Multari, A. G., Conca, R., & Aieta, M. (2018). Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study. Medicine (Baltimore).

Chicago Style Citation

Roviello, Giandomenico, Roberto Petrioli, Valerio Nardone, Pietro Rosellini, Andrea Giovanni Multari, Raffaele Conca, i Michele Aieta. "Docetaxel, Oxaliplatin, 5FU, and Trastuzumab As First-line Therapy in Patients With Human Epidermal Receptor 2-positive Advanced Gastric or Gastroesophageal Junction Cancer: Preliminary Results of a Phase II Study." Medicine (Baltimore) 2018.

Cita MLA

Roviello, Giandomenico, et al. "Docetaxel, Oxaliplatin, 5FU, and Trastuzumab As First-line Therapy in Patients With Human Epidermal Receptor 2-positive Advanced Gastric or Gastroesophageal Junction Cancer: Preliminary Results of a Phase II Study." Medicine (Baltimore) 2018.